Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Detroit, Michigan

This page shows live ClinicalTrials.gov search results for Detroit, Michigan, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
7245
Shown on this page
12
Current sort
Recently updated
Location scope
Detroit, MI
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Detroit, Michigan. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 469–480 of 7,245 matching trials in Detroit, MI.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

NCT06244771
View directory record Official record
Conditions
Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor, Non Small Cell Lung Cancer, KRAS G12C
Interventions
FMC-376
Drug
Lead sponsor
Frontier Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
15
States / cities
La Jolla, California • Orange, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 5:01 PM EST
Active, not recruiting Phase 2 Interventional

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

NCT04266249
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions
Docetaxel, Lumpectomy, Mastectomy, Nab-paclitaxel, Paclitaxel, Pertuzumab, Radiation Therapy, Trastuzumab, Trastuzumab Emtansine
Drug · Procedure · Biological + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
2,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2038
U.S. locations
999
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 5:01 PM EST
Active, not recruiting Phase 2 Interventional

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

NCT04316117
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 5, 2026, 5:01 PM EST
Active, not recruiting Phase 3 Interventional

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

NCT06389136
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib 15mg Dose, Dupilumab 300mg Dose, Upadacitinib 30mg Dose
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 63 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 5, 2026, 5:01 PM EST
Recruiting Phase 3 Interventional

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

NCT07218146
View directory record Official record
Conditions
Small-cell Lung Cancer
Interventions
ZL-1310, Investigator's Choice of Therapy
Drug
Lead sponsor
Zai Lab (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
La Jolla, California • Sacramento, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 5, 2026, 5:01 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

NCT07300839
View directory record Official record
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 Vaccine, Placebo
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
50 Years to 64 Years
Enrollment
5,240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
196
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 148 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 5, 2026, 5:01 PM EST
Active, not recruiting Phase 2 Interventional

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07474792
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ORKA-002, Placebo
Drug · Other
Lead sponsor
Oruka Therapeutics, Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 5, 2026, 5:01 PM EST
Completed Phase 3 Interventional

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

NCT04225871
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
zilucoplan (RA101495)
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
33
States / cities
Mobile, Alabama • Phoenix, Arizona • Irvine, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 5, 2026, 5:01 PM EST
Recruiting No phase listed Observational

Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

NCT07676565
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
17
States / cities
Newport Beach, California • San Francisco, California • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 5, 2026, 5:01 PM EST
Recruiting Phase 3 Interventional

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875
View directory record Official record
Conditions
HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Interventions
Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, 5-fluorouracil, Capecitabine, Cisplatin, Oxaliplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
58
States / cities
Anchorage, Alaska • Phoenix, Arizona • Duarte, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 5, 2026, 5:01 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

NCT06143891
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Belumosudil, Placebo, Prednisone, Prednisolone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
24
States / cities
Little Rock, Arkansas • Duarte, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 5, 2026, 5:01 PM EST
Recruiting No phase listed Observational

Global Paradise System US Post Approval Study

NCT06297291
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions
Paradise Ultrasound Renal Denervation Treatment
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
46
States / cities
Long Beach, California • Los Angeles, California • Sacramento, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 5, 2026, 5:01 PM EST